Analysts Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Price Target at $33.25

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) have been assigned a consensus rating of “Moderate Buy” from the ten brokerages that are currently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $33.25.

Several analysts have recently weighed in on the stock. Barclays initiated coverage on shares of 4D Molecular Therapeutics in a research report on Wednesday, January 28th. They set an “overweight” rating and a $33.00 target price on the stock. Leerink Partners restated an “outperform” rating and set a $17.00 price target on shares of 4D Molecular Therapeutics in a research note on Friday, October 31st. Royal Bank Of Canada reiterated an “outperform” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, January 7th. Chardan Capital reissued a “buy” rating and issued a $26.00 target price on shares of 4D Molecular Therapeutics in a report on Thursday, December 18th. Finally, Morgan Stanley raised 4D Molecular Therapeutics from an “underweight” rating to an “equal weight” rating in a research note on Friday, November 7th.

Institutional Investors Weigh In On 4D Molecular Therapeutics

A number of hedge funds have recently made changes to their positions in FDMT. Dimensional Fund Advisors LP increased its stake in shares of 4D Molecular Therapeutics by 3.7% in the 3rd quarter. Dimensional Fund Advisors LP now owns 58,006 shares of the company’s stock valued at $504,000 after acquiring an additional 2,069 shares during the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of 4D Molecular Therapeutics by 11.7% during the 2nd quarter. Russell Investments Group Ltd. now owns 21,816 shares of the company’s stock valued at $81,000 after purchasing an additional 2,284 shares in the last quarter. Prelude Capital Management LLC grew its position in shares of 4D Molecular Therapeutics by 11.1% in the 3rd quarter. Prelude Capital Management LLC now owns 23,000 shares of the company’s stock valued at $200,000 after purchasing an additional 2,300 shares during the period. Farther Finance Advisors LLC grew its position in shares of 4D Molecular Therapeutics by 117.4% in the 3rd quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock valued at $43,000 after purchasing an additional 2,674 shares during the period. Finally, Peapod Lane Capital LLC increased its stake in 4D Molecular Therapeutics by 1.1% during the 3rd quarter. Peapod Lane Capital LLC now owns 322,081 shares of the company’s stock worth $2,799,000 after purchasing an additional 3,544 shares in the last quarter. Institutional investors and hedge funds own 99.27% of the company’s stock.

4D Molecular Therapeutics Trading Up 7.2%

Shares of NASDAQ:FDMT opened at $8.99 on Thursday. The firm has a market capitalization of $513.60 million, a PE ratio of -2.40 and a beta of 3.01. 4D Molecular Therapeutics has a 1-year low of $2.23 and a 1-year high of $12.34. The business’s 50 day moving average is $8.77 and its 200-day moving average is $8.47.

4D Molecular Therapeutics (NASDAQ:FDMT) last issued its earnings results on Monday, November 10th. The company reported ($1.01) EPS for the quarter, topping the consensus estimate of ($1.02) by $0.01. The firm had revenue of $0.09 million during the quarter, compared to analysts’ expectations of $0.40 million. 4D Molecular Therapeutics had a negative return on equity of 47.27% and a negative net margin of 174,314.17%. On average, sell-side analysts predict that 4D Molecular Therapeutics will post -2.84 EPS for the current year.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.